Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node

Laryngoscope Investigative Otolaryngology

article

Wan-Yu Chen MD¹  Ku-Hao Fang MD⁴  Chun-Wei Wang MD, PhD¹  Chun-Ta Liao MD⁴  Tzu-Chen Yen MD, PhD⁷  Taun-Jen Fang MD, PhD⁴  Shih-Fan Lai MD¹  Hsiang-Kuang Liang MD, PhD¹  Bing-Shen Huang MD⁸ 

[1] Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital;Graduate Institute of Clinical Medicine, National Taiwan University;National Taiwan University Cancer Center;Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital and Chang Gung University;Cancer Research Center, National Taiwan University College of Medicine;Department of Radiology, College of Medicine, National Taiwan University;Department of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital and Chang Gung University;Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University

关键词: adjuvant radiotherapy;    oral cancer;    risk factor;    single node;    surgery;   

DOI  :  10.1002/lio2.679

学科分类：环境科学（综合）

来源: Wiley

【 摘 要 】

Objective Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1 new in this study). Methods A total of 243 low/intermediate risk pN1 new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone. Results For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5-year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1 new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1 new patients. Conclusion For low/intermediate risk pN1 new patients with oral cavity cancer, adjuvant therapy might be omitted. Level of Evidence 4.

【 授权许可】

CC BY|CC BY-NC-ND